Literature DB >> 8939274

Progression of selective IgA deficiency to common variable immunodeficiency in a 16 year old boy.

J Litzman1, M Burianova, V Thon, J Lokaj.   

Abstract

A case report of a 16 year old boy in whom selective IgA deficiency progressed to typical common variable immunodeficiency (CVID) is described. This boy with a history of frequent but not severe respiratory tract infections was referred to hospital because of severe pleuropneumonia and decreased levels of IgA (0.23 g/L), but normal IgG and IgM levels. Lymphocyte subpopulation determination revealed a decreased proportion of CD4+ lymphocytes (30%) and an increased proportion of CD8+ lymphocytes (32%), while CD3+, CD19+ and CD16+/56+ subpopulations were normal. During the subsequent 17 months a gradual decrease in IgG (ultimate level 2.23 g/L), IgA (< 0.05 g/L) and IgM (< 0.05 g/L) levels was observed, the decrease in IgM being the slowest reflecting a constant heavy chain gene order on chromosome 14. The observation supports the thesis of a close relation of selective IgA deficiency and common variable immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8939274

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  3 in total

Review 1.  Lung Disease in Primary Antibody Deficiencies.

Authors:  Edith Schussler; Mary B Beasley; Paul J Maglione
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

2.  Asthma and risk of selective IgA deficiency or common variable immunodeficiency: a population-based case-control study.

Authors:  Sang-Hwa Urm; Hyun Don Yun; Yilma A Fenta; Kwang Ha Yoo; Roshini S Abraham; John Hagan; Young J Juhn
Journal:  Mayo Clin Proc       Date:  2013-08       Impact factor: 7.616

3.  Risk factors of partial IgA deficiency among low serum IgA patients: a retrospective observational study.

Authors:  Kazuki M Matsuda; Hiroko Arioka; Daiki Kobayashi
Journal:  Cent Eur J Immunol       Date:  2020-07-27       Impact factor: 2.085

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.